Skip to main content

Infectious Disease Firm Day Zero Diagnostics Raises $8.6M in Series A Round

NEW YORK (GenomeWeb) – Boston-based startup Day Zero Diagnostics said today that it has raised $8.6 million in a Series A funding round.

DZD will use the funding to expedite prototype development of its sample preparation technology and computational approach. According to the firm, the funds will also help introduce DZD Lab Services, a set of sequencing-based diagnostic services to "help clinicians address critical infection situations and transmission events."

The funding round was led by Triventures with significant participation from existing investors including Sands Capital Ventures and Golden Seeds. As part of the financing, Peter Fitzgerald, a managing partner at Triventures, will join DZD's board of directors.

DZD is developing a sequencing-based diagnostic assay that it said quickly identifies both the species of a bacterial pathogen and its antibiotic resistance profile.

"This funding allows us to continue our diagnostic system development effort and to expand our research and development program to additional use cases in infectious disease where speed and precision matter," DZD CEO and Cofounder Jong Lee said in a statement.

The company was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.